BioPharma Dive December 9, 2024
Ben Fidler

The firm’s co-founders claim to be pursuing a “contrarian” approach, building a team equally versed in both computing and life sciences.

Dive Brief:

  • Dimension, a young biotech venture firm run by former Lux Capital and Obvious Ventures investors, has raised its second fund in two years.
  • Called Dimension II, the $500 million fund announced Monday surpasses the $350 million the firm debuted with in January 2023. Like the earlier fund, Dimension II will support companies working at the “interfaces of life science and technology,” its three co-founders and managing partners wrote in a blog post. It’s investing in tech-powered therapeutics companies as well as developers of tools and manufacturing techniques that aid in drugmaking and discovery.
  • In an interview,...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, Investments, Pharma / Biotech, Trends
AbbVie Enters Obesity Field, Paying $350M for Amylin Receptor Agonist Already in the Clinic
2025 Drugs to Watch: Market Access, Innovation, and the Future of Reimbursement
Renowned Geneticist Francis Collins, MD, PhD, Retires from NIH
How AI Is Transforming The Pharmaceutical Industry
MHE Week in Review – Medicaid Cuts, Congressional PBM Hearing and More

Share This Article